Drug discovery efforts complemented by CNS Profile™, our novel, proprietary platform based on Nobel Prize–winning science

 

Based on the pioneering efforts of ITCI co-founder and Nobel laureate, Dr. Paul Greengard, we have developed a detailed understanding of intracellular signaling pathways and intracellular targets. We have used that knowledge to develop several technology platforms, including one called CNSProfile.We have used that knowledge to develop several technology platforms, including one called CNSProfile This technology monitors the phosphoprotein changes elicited by major psychotropic drug classes and subclasses, and generates a unique molecular signature for drug compounds. By monitoring how the levels of these phosphoproteins change in vivo, we identify intracellular signaling pathways through which several major drug classes operate. We have used, and may continue to use, this information as a tool to validate our selection of preclinical candidate molecules.